If you know about any current or published study on CML and COVID-19, please, let us know by contacting us
Please also visit the iCMLF COVID-19 hub to view a list of other relevant articles.
Published online May 18, 2020, https://doi.org/10.1038/s41375-020-0853-6
COVID-19 in persons with chronic myeloid leukaemia
Authors: Weiming Li, Danyu Wang, Jingming Guo, Guolin Yuan, Zhuangzhi Yang, Robert Peter Gale, Yong You, Zhichao Chen, Shiming Chen, Chucheng Wan, Xiaojian Zhu, Wei Chang, Lingshuang Sheng, Hui Cheng, Youshan Zhang, Qing Li, Jun Qin, Hubei Anti-Cancer Association, Li Meng & Qian Jiang.
Our survey suggests that although persons with CML receiving TKI-therapy developing COVID-19 may be higher than the general population the absolute case-rate is very low and clinical features are like normals. Persons with no Complete Hematological Response, with co-morbidity(ies), with advanced phase at diagnosis despite responding to TKI-therapy and those exposed to someone with SARS-CoV-2-infection may benefit from increased surveillance and possible protective isolation
Published online May 7, 2020, 10.1111/bcp.14353
Chronic myeloid leukemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic
Author: Eşkazan AE.
To date, patients with CML-CP on TKI therapy were not shown to be at increased risk for COVID-19 disease, although not sufficient data is available yet...So, close monitoring with serial ECGs is necessary together with prompt and timely dose modifications of these drugs in patients with CML and COVID-19 disease
Published online April 27, 2020, https://doi.org/10.4084/MJHID.2020.031
SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a case report and review of ABL kinase involvement in viral infectionc
Authors: Elisabetta Abruzzese, Luigiana Luciano, Francesco D'Agostino, Malgorzata Monika Trawinska, Fabrizio Pane, Paolo De Fabritiis
The incidence and severity of SARS-CoV-2 virus infection may not be worse in CML patients who are being treated with TKIs than in virus victims without an underlying CML diagnosis. Moreover, CML patients who contract SARS-CoV-2 may even be protected by TKI therapy.
Published online April 13, 2020, doi:10.1001/jama.2020.6019 JAMA
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19). A Review.
Authors: Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB.
Several other immunomodulatory agents traditionally used for noninfectious indications demonstrate in vitro activity or possess mechanisms purported to inhibit SARS-CoV-2, including, but not limited to, baricitinib, imatinib, dasatinib, and cyclosporine.”
Published: March 25, 2020, The Lancet
The First Report of the Prevalence of COVID-19 in Chronic Myelogenous Leukemia Patients in the Core Epidemic Area of China: A Multicentre, Cross-Sectional Survey
Authors: Wei-Ming Li, M.D, Wuhan Union Hospital, Wuhan, Hubei CHINA et al (2020).
Patients who failed to achieve an optimal response to CML therapy appear more likely to have a symptomatic infection with SARS-CoV-2